【US Stock Market Movement】Circle surged on October 9: SAP payments + USDC expansion + stablecoins
Bitget异动解读2026/10/09 14:30Circle October 9th Surge Analysis
Keywords: SAP payments, USDC expansion, stablecoins
1. On October 7th, Circle partnered with financial services company Tereina, supported by SAP, to introduce USDC and EURC into enterprise payment processes, and to promote the application to SAP customers through SAP Pay.
2. On October 7th, Samsung announced support for stablecoin transfers in Samsung Wallet and Samsung Pay, initially covering 82 million Galaxy devices in the United States. Users can use USDC for cross-border remittances.
3. On October 8th, Securitize launched 12 tokenized U.S. equity products, including Circle, with token trading conducted on Solana and settled in USDC. During the same period, capital inflows into the digital asset market and the performance of crypto assets attracted attention.
(Disclaimer: This content is a summary of publicly available information collected by AI technology and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cross-chain atomic transactions between Ethereum mainnet and L2
US Stock Movement | US clinical-stage biopharmaceutical company Retension Pharmaceuticals (RTSN.US) enters the US stock market, shares drop over 10% after opening
According to Jinse Finance, Retension Pharmaceuticals (RTSN.US) debuted on the US stock market on Friday and fell over 10% to $10.77 at press time, with an IPO price of $12. Retension Pharmaceuticals is a US-based clinical-stage biopharmaceutical company focused on developing innovative drugs for the treatment of hypertension and other cardiovascular diseases. The company's core investigational drug, RTN-001, is a new generation phosphodiesterase 5 (PDE5) inhibitor, primarily targeting patients with uncontrolled or resistant hypertension, and is currently undergoing a Phase IIb clinical trial. This drug works by enhancing nitric oxide signaling in blood vessels to promote vasodilation and lower blood pressure. The exclusive global development license comes from French pharmaceutical giant Sanofi (SNY.US).
Crypto prices
More
